Hera Biotech Announces Positive Interim Results From Endometriosis Diagnostic Study

SAN ANTONIO--(BUSINESS WIRE)-- #biotech--Hera Biotech is pleased to report the interim results for its proof-of-concept multi-center clinical trial of the MetriDx™ endometriosis diagnostic test. Per protocol data from the first 38 patients who have been enrolled in the 60 patient study shows that the diagnostic test is performing with 92% sensitivity, 95% specificity and an overall accuracy (AUC) of 94%, as compared to the histopathology of excised lesions. “This result suggests that Hera’s molecular diag